{"id":40921,"date":"2025-07-07T13:09:40","date_gmt":"2025-07-07T12:09:40","guid":{"rendered":"https:\/\/bnssghealthiertogether.org.uk\/?page_id=40921"},"modified":"2025-12-03T09:05:18","modified_gmt":"2025-12-03T09:05:18","slug":"tirzepatide-mounjaro","status":"publish","type":"page","link":"https:\/\/bnssghealthiertogether.org.uk\/ps\/tirzepatide-mounjaro\/","title":{"rendered":"Tirzepatide (Mounjaro\u00ae)"},"content":{"rendered":"
Section titled module-1<\/span><\/a>
\r\n
\r\n

New medication for weight loss: Tirzepatide (Mounjaro\u00ae)<\/strong><\/h1>\n

<\/p>\n

Tirzepatide, commonly known as Mounjaro\u00ae, is a new medication recently recommended by the National Institute for Health and Care Excellence (NICE) for some adults living with obesity.<\/p>\n

Access to tirzepatide (Mounjaro\u00ae) through your GP practice<\/strong><\/h2>\n

From 23 June 2025 GP practices can begin offering tirzepatide (Mounjaro\u00ae). This does not mean the medicine will be prescribed straight away or available immediately.<\/p>\n

Tirzepatide (Mounjaro\u00ae) will initially be offered by some NHS GPs in a staged rollout. In the first year, it will only be offered to people with a BMI of 40 or more (or 37.5 in certain ethnic groups) who are also managing four or more health conditions \u2013 These are, hypertension, Type 2 diabetes, sleep apnoea, hyperlipidaemia (high cholesterol) and cardiovascular disease. These need to be diagnosed by a healthcare professional.<\/p>\n

This priority patient group has been nationally set and has been focused to support people facing the greatest risk of, or who are experiencing, severe ill health due to obesity.<\/p>\n

Tirzepatide (Mounjaro\u00ae) must be prescribed as part of a support programme, also known as wraparound care. This includes advice on healthy eating, physical activity, and lifestyle changes. You must agree to take part in this support to receive the medication.<\/p>\n

Requesting tirzepatide (Mounjaro\u00ae) for weight loss<\/strong><\/h2>\n

We know that many people are asking about tirzepatide (Mounjaro\u00ae) after hearing about how effective it can be in helping with weight loss.<\/p>\n

As your Integrated Care Board (ICB), and following national guidance, we must make sure treatments are used fairly and within the budget we have available for our population.<\/p>\n

We appreciate that this might feel frustrating, especially when private options are being advertised.<\/p>\n

Please do not contact your GP surgery to request tirzepatide (Mounjaro\u00ae) for weight loss. We are working with GP surgeries across Bristol, North Somerset and South Gloucestershire to support them to be able to offer tirzepatide (Mounjaro\u00ae) to priority patient groups.<\/p>\n

GP surgeries will contact priority patients to invite them to make an appointment to find out more.<\/p>\n

For more information about tirzepatide (Mounjaro\u00ae) in Bristol, North Somerset and South Gloucestershire, please see the frequently asked questions below.<\/p>\n

Frequently asked questions<\/h2>\n

 <\/p>\n <\/div>\r\n <\/section><\/div>

Section titled module-2<\/span><\/a>
\n\n

\n Can I get tirzepatide (Mounjaro\u00ae) now? <\/i>\n <\/h3>\n\n
\n
\n

Please do not contact your GP to request it \u2014 you\u2019ll be contacted directly if you\u2019re eligible when the service becomes available in your area.
\nWe expect most GPs to begin offering tirzepatide(Mounjaro\u00ae) to eligible patients over the summer of 2025, but a wider rollout may take longer.<\/p>\n

 <\/p>\n <\/div>\n <\/section>\n\n<\/section>\n<\/div>

Section titled module-3<\/span><\/a>
\n\n

\n Why is access being rolled out in stages? <\/i>\n <\/h3>\n\n
\n
\n

The NHS needs time to safely introduce this new service, train healthcare staff, and manage demand.<\/p>\n

A staged rollout allows those with the greatest clinical need to be prioritised first and ensures safe and sustainable delivery.<\/p>\n

 <\/p>\n <\/div>\n <\/section>\n\n<\/section>\n<\/div>

Section titled module-4<\/span><\/a>
\n\n

\n What is being done to prepare? <\/i>\n <\/h3>\n\n
\n
\n

We\u2019re developing a new approach to provide access to tirzepatide (Mounjaro\u00ae) through GP practices.<\/p>\n